Biohaven公布癫痫新药Opakalim最新临床数据:选择性Kv7.2/7.3激活剂展现良好癫痫控制与显著差异化耐受性特征

美股速递
May 26

Biohaven公司近日公布了其选择性Kv7.2/7.3激活剂Opakalim在癫痫治疗领域的最新临床数据。结果显示,该药物在癫痫控制方面表现出积极效果,并且其耐受性特征与现有疗法相比呈现出显著差异化优势。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10